Balsm Alofoq Medical Company (9620) Fair Value & Analysis
Healthcare · SA · Market cap 61.2M SAR
Fair value as of: Aug 1, 2026
From 15 valuation models · updated today
Share price +2.0% over the past month.
What matters now
- The price sits above even our optimistic bull case (14.52 SAR). The favourable scenario is already priced in.
- Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (7.82 SAR to 14.52 SAR) leaves room in how you read the outcome.
Price vs Fair Value (12 months)
12‑month range 22.50 SAR – 37.00 SAR · fair‑value band 7.82 SAR – 14.52 SAR · the 24.49 SAR price screens above the 11.17 SAR fair value. As of Aug 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Balsm Alofoq Medical Company (9620) currently trades at 24.49 SAR, while our model-based Fair Value estimate is 11.17 SAR, implying the stock looks roughly 54.4% overvalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Balsm Alofoq Medical Company generated revenue of 20.4M SAR at a net margin of 9.7%. Revenue grew 3.0% year over year. It earns a return on equity of 6.6%. The balance sheet holds a net cash position of 16.4M SAR. Fundamentals as of Aug 1, 2026
Our scenario range runs from 7.82 SAR (bear case) to 14.52 SAR (bull case); at 24.49 SAR, the current price sits above that range. The share trades about 34% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -29% fair-value upside, at -54%, 9620 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Balsm Alofoq Medical Company provides various services and solutions for medical sector in the Kingdom of Saudi Arabia. It is involved in operation of hospitals, specialized medical complexes, general medical complexes, medical clinics, day surgery centers, and medical laboratories; wholesale and retail of medical devices, equipment, and supplies; operation …
Full company description
Balsm Alofoq Medical Company provides various services and solutions for medical sector in the Kingdom of Saudi Arabia. It is involved in operation of hospitals, specialized medical complexes, general medical complexes, medical clinics, day surgery centers, and medical laboratories; wholesale and retail of medical devices, equipment, and supplies; operation of hazardous waste treatment facilities; medical equipment and product warehouses; social welfare institutions; identification and distribution of social assistance; daycare for people with special needs; adoption services; transportation of hazardous medical waste; installation of machinery and equipment; and counseling for families and individuals. Balsm Alofoq Medical Company was incorporated in 2012 and is based in Buraydah, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Balsm Alofoq Medical Company reported revenue of 20.4M SAR in FY2025 versus 17.0M SAR in FY2022, a compound +6.2%/yr. Reported net income was 2.0M SAR in FY2025, compounding −17.6%/yr from FY2022.
Is 9620 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $90.53 | $79.67 | -12% |
| Stryker Corporation SYK | $310.00 | $186.28 | -40% |
| Medtronic plc 2M6 | €64.08 | €37.00 | -42% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| STERIS plc S1TE34 | R$52.14 | R$8.02 | -85% |
| Zimmer Biomet Holdings Z1BH34 | R$119.88 | R$85.65 | -29% |
| Shanghai United Imaging Healthcare Co 688271 | ¥104.19 | ¥45.36 | -56% |
Compare Balsm Alofoq Medical Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Balsm Alofoq Medical Company (9620) overvalued or undervalued?
What is the fair value of 9620?
What is the quality score of 9620?
What is the revenue of Balsm Alofoq Medical Company (9620)?
What is the net profit margin of 9620?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Balsm Alofoq Medical Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.